I85PREP
⌘ K
MAB Registration Exam study materials
MAB Registration Exam study resources

MAB Registration Exam practice questions

One question at a time. Build your MAB Registration Exam understanding.

First 50 of 200 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

Which activity falls within the core remit of a Medical Affairs department in a life sciences company rather than the commercial organization?

  1. Designing and approving promotional campaign messaging
  2. Managing wholesaler inventory and distribution logistics
  3. Scientific exchange with external experts and medical information response Correct answer.
  4. Setting list price and negotiating payer rebates

Explanation

Medical Affairs exists to generate and communicate scientific evidence and to support non-promotional scientific exchange, including medical information responses and engagement with external experts. Pricing, rebates, and distribution are commercial and supply-chain functions, and promotional messaging is owned by commercial with medical review rather than medical authorship.

Question 2Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

A company's Medical Science Liaisons are being briefed on their field role. Which description best reflects the accepted purpose of the MSL function?

  1. To negotiate formulary access with hospital pharmacy committees
  2. To process adverse event reimbursement claims for patients
  3. To drive prescription volume by detailing products to high-prescribing physicians
  4. To serve as a non-promotional scientific resource who gathers and shares clinical insight Correct answer.

Explanation

The MSL role is defined as non-promotional scientific exchange: responding to unsolicited requests, presenting fair-balanced data, and capturing insights that inform medical strategy. MSLs do not carry sales targets or detail products, and access negotiation and reimbursement processing belong to other functions.

Question 3Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

During a Phase III program, a sponsor's Medical Affairs team is asked to plan evidence-generation activities. Which pair of activities most appropriately sits with Medical Affairs?

  1. Investigator-initiated study support and real-world evidence generation Correct answer.
  2. Manufacturing batch release and stability testing
  3. Sales force sizing and territory alignment
  4. Advertising agency selection and media buying

Explanation

Medical Affairs commonly sponsors or supports investigator-initiated research, collaborative studies, and real-world evidence that address gaps beyond the registrational program. Commercial analytics, manufacturing quality, and advertising procurement are functions of other departments.

Question 4Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

A physician emails a company's medical information desk asking for data on an off-label use of a marketed drug. Under typical industry codes and regulations, how should the Medical Affairs team respond?

  1. Provide a balanced, referenced response through the medical information function Correct answer.
  2. Send promotional reprints with a sales message attached
  3. Forward the request to the sales representative covering that territory
  4. Refuse any response because the question concerns an unapproved use

Explanation

Responding to unsolicited requests for off-label information is a recognized medical information activity, provided the response is scientific, balanced, referenced, and delivered through appropriate non-promotional channels. Refusing outright is not required, and routing to sales or attaching promotional content would convert the exchange into promotion.

Question 5Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

Which statement best distinguishes the Medical Affairs function from the commercial function in a pharmaceutical company?

  1. Medical Affairs holds scientific accountability and is organizationally independent of sales targets Correct answer.
  2. Medical Affairs reports to the sales director and shares prescription quotas
  3. Medical Affairs owns brand positioning and promotional budget allocation
  4. Medical Affairs sets the wholesale acquisition cost for each product

Explanation

Medical Affairs carries scientific accountability and must be structurally separated from commercial incentives so that its judgments are not influenced by sales targets. Brand positioning and promotional budgets are commercial deliverables, and pricing is set by commercial and market access leadership.

Question 6Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

A Medical Affairs team is building a publication plan for a new asset. Which principle should govern authorship and editorial decisions?

  1. Authorship should reflect substantive scientific contribution, with no ghost or gift authorship Correct answer.
  2. Only company employees may be listed as authors
  3. Publication timing should be set to coincide with promotional launch events
  4. Commercial approval is required before any manuscript is submitted

Explanation

Good publication practice requires that authorship be based on substantive intellectual contribution and that all contributors be disclosed, excluding ghost and gift authorship. Commercial approval of manuscripts and launch-timed publication are inappropriate influences, and external investigators frequently qualify as authors.

Question 7Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

Which of the following best describes the purpose of a Medical Affairs medical strategy plan?

  1. To define the scientific narrative, evidence gaps, and medical activities aligned to unmet need Correct answer.
  2. To determine the advertising spend across media channels
  3. To forecast quarterly sales and set revenue targets by region
  4. To specify the manufacturing process validation schedule

Explanation

A medical strategy plan articulates the scientific story, identifies evidence gaps, and sequences medical activities such as studies, publications, and expert engagement. It is a scientific and evidence-oriented document, distinct from sales forecasting, process validation, and advertising budgets.

Question 8Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

A company plans to hold an advisory board with external clinical experts. Which practice best aligns with compliance expectations for Medical Affairs advisory boards?

  1. Hold the meeting at a resort with spouses invited to increase attendance
  2. Select attendees primarily for their prescription volume and pay honoraria above fair market value
  3. Choose participants for relevant expertise, pay fair market value, and document a legitimate scientific need Correct answer.
  4. Keep the meeting agenda confidential from the compliance function

Explanation

Advisory boards must serve a genuine scientific need, use participants selected for expertise, and compensate them at fair market value with appropriate documentation. Selecting by prescribing volume, inflating honoraria, adding leisure, or concealing the agenda from compliance are classic compliance failures.

Question 9Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

Which document typically defines the scientific exchange boundaries and approved data for field medical personnel when responding to unsolicited requests?

  1. The manufacturing deviation report
  2. The sales incentive compensation plan
  3. The corporate travel and expense policy
  4. The standard medical response letter and approved medical slide library Correct answer.

Explanation

Field medical personnel rely on approved medical response documents and standardized slide decks that have been through medical, legal, and regulatory review. These tools ensure responses are accurate, balanced, and consistent, whereas incentive plans, deviation reports, and travel policies have no bearing on scientific content.

Question 10Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

A payer requests a dossier summarizing clinical and economic evidence for a new therapy. Which Medical Affairs contribution is most appropriate?

  1. Negotiating the contract terms with the payer
  2. Authoring the clinical sections and ensuring scientific accuracy of the value dossier Correct answer.
  3. Approving the payer's formulary tier placement
  4. Setting the confidential rebate level offered to the payer

Explanation

Medical Affairs supports value dossiers by supplying accurate clinical evidence, fair-balanced interpretation, and scientific review, often in partnership with market access. Rebate levels, formulary tier decisions, and contract negotiation are payer-facing commercial and access activities outside medical's remit.

Question 11Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

Which of the following is the primary reason Medical Affairs reviews promotional materials?

  1. To reduce the printing costs of marketing collateral
  2. To increase the promotional claims that can be made about a product
  3. To verify scientific accuracy and fair balance of the claims and references Correct answer.
  4. To shorten the regulatory submission timeline

Explanation

Medical review of promotional materials focuses on scientific accuracy, fair balance, and correct citation of supporting evidence, and it often carries sign-off authority alongside regulatory and legal. Its purpose is not to expand claims, cut costs, or accelerate regulatory submissions.

Question 12Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

A Medical Affairs team wants to measure the impact of its field medical activities. Which set of metrics is most aligned with medical objectives?

  1. Market share change in each sales territory
  2. Quality and number of scientific exchanges and insights that informed medical strategy Correct answer.
  3. Number of prescriptions written after each MSL visit
  4. Average revenue per representative

Explanation

Medical impact is assessed through indicators such as the volume and quality of scientific exchanges, insight generation that shapes strategy, and evidence dissemination. Prescription counts, market share, and revenue per representative are commercial metrics that do not reflect medical value.

Question 13Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

Which statement most accurately describes the relationship between Medical Affairs and Regulatory Affairs during a marketing application review?

  1. The two functions are fully merged and share a single budget
  2. Medical Affairs has no interaction with regulatory submissions
  3. Medical Affairs writes the regulatory submission and Regulatory Affairs reviews promotional materials
  4. Regulatory Affairs leads the submission while Medical Affairs provides clinical and scientific input and supports responses to questions Correct answer.

Explanation

Regulatory Affairs owns the marketing application and agency interactions, while Medical Affairs contributes scientific and clinical content and helps craft responses to agency questions. The roles are complementary rather than merged, and medical does have substantive input to submissions.

Question 14Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

A phase IV study is being designed to evaluate a product in a broader patient population after approval. Which function typically leads the scientific design while Medical Affairs supports execution and communication?

  1. Clinical development or medical research, with Medical Affairs supporting publication and dissemination Correct answer.
  2. The sales organization, which designs the protocol to maximize prescriptions
  3. The legal department, which designs the statistical analysis plan
  4. The finance department, which designs endpoints around cost savings

Explanation

Late-phase and post-approval studies are scientifically designed by clinical development or medical research groups, with Medical Affairs often contributing to execution, site relationships, and dissemination of results. Sales, finance, and legal do not design study protocols or statistical plans.

Question 15Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

Which behavior by an MSL would most likely breach the boundary between medical and commercial activity?

  1. Presenting fair-balanced clinical data at a scientific congress
  2. Accepting a sales target and tracking prescriptions in the CRM Correct answer.
  3. Responding to an unsolicited scientific question with approved data
  4. Documenting a clinical insight from an external expert

Explanation

MSLs must remain non-promotional and free of sales targets; accepting a prescription target and tracking prescribing would convert the role into sales. Responding to unsolicited questions, presenting at congresses, and recording insights are legitimate field medical activities.

Question 16Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

A company is preparing for a product launch. Which launch-readiness activity is most clearly owned by Medical Affairs?

  1. Building the scientific platform, medical education content, and expert engagement plan Correct answer.
  2. Training the sales force on objection-handling scripts
  3. Finalizing the advertising media schedule
  4. Setting the launch price and discount strategy

Explanation

Medical launch readiness centers on the scientific platform, disease and product education for external stakeholders, evidence dissemination, and expert engagement planning. Sales training scripts, media schedules, and pricing strategy are commercial deliverables.

Question 17Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

Which of the following best describes the concept of a target product profile from a Medical Affairs perspective?

  1. A schedule of manufacturing site inspections
  2. A record of patient copay assistance payments
  3. A summary of the desired labeling claims and clinical attributes that guides development and evidence planning Correct answer.
  4. A list of the sales representatives assigned to each territory

Explanation

The target product profile describes the intended labeling, clinical attributes, and differentiation the program aims to achieve, and Medical Affairs uses it to plan the evidence needed to support those claims. Territory assignments, inspection schedules, and copay records are unrelated operational documents.

Question 18Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

An external expert asks an MSL for information on a competitor's product that is not in the approved medical response library. What is the most appropriate action?

  1. Decline to speculate and route the question to medical information for a documented response Correct answer.
  2. Promise to send promotional material that favors the company's product
  3. Speculate based on personal reading of the literature during the visit
  4. Compare the competitor unfavorably using unpublished internal data

Explanation

MSLs should not speculate or make unsupported comparative claims; questions outside approved materials are routed to medical information so a documented, referenced response can be prepared. Using unpublished internal data or sending promotional material would breach scientific exchange standards.

Question 19Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

Which statement best captures how Medical Affairs contributes to patient-centricity in the life sciences industry?

  1. By setting patient copay levels for commercial products
  2. By incorporating patient-reported outcomes and patient experience data into evidence generation and medical communications Correct answer.
  3. By approving patient advocacy group budgets
  4. By enrolling patients directly into clinical trials without informed consent

Explanation

Medical Affairs advances patient-centricity by integrating patient-reported outcomes, patient preference, and real-world experience into evidence and communication. Enrolling patients without consent is unethical, and copay levels and advocacy budgets are commercial or corporate affairs matters.

Question 20Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

A Medical Affairs team is asked to define the difference between medical education and promotional education. Which distinction is correct?

  1. Medical education is always delivered by sales representatives
  2. Promotional education must be free of any product claims
  3. The two terms are interchangeable in industry practice
  4. Medical education is non-promotional and scientifically balanced, while promotional education is designed to support product sales Correct answer.

Explanation

Medical education is non-promotional, balanced, and focused on disease and scientific understanding, whereas promotional education is designed to support product promotion and is governed by promotional rules. Medical education is not delivered by sales, promotional education does contain product claims, and the terms are not interchangeable.

Question 21Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

Which of the following is the most appropriate role for Medical Affairs in the management of a safety signal identified during post-marketing surveillance?

  1. Provide clinical context and scientific assessment to support pharmacovigilance evaluation Correct answer.
  2. Independently decide whether to withdraw the product from the market
  3. Set the price of the product after the signal is resolved
  4. Suppress the signal to protect commercial sales

Explanation

Pharmacovigilance leads signal detection and regulatory reporting, while Medical Affairs contributes clinical interpretation and scientific context to the assessment. Market withdrawal decisions rest with regulatory and senior management, suppressing signals is unlawful, and pricing is unrelated.

Question 22Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

Which of the following best describes the role of a medical information call center within Medical Affairs?

  1. It manages the company's social media advertising accounts
  2. It provides accurate, balanced, documented responses to unsolicited scientific and medical inquiries Correct answer.
  3. It conducts sales calls to prescribers on behalf of the commercial team
  4. It handles product orders and shipping inquiries from pharmacies

Explanation

The medical information function responds to unsolicited medical and scientific inquiries with accurate, balanced, referenced answers and documents each interaction. Order handling, sales calls, and advertising management belong to other functions.

Question 23Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

A company wants to establish a patient support program that includes education on disease management. Which Medical Affairs contribution is most appropriate?

  1. Approving the program's marketing taglines for television
  2. Selecting the program's third-party logistics vendor
  3. Designing the program's copay coupon amounts
  4. Reviewing the educational content for scientific accuracy and fair balance Correct answer.

Explanation

Medical Affairs reviews patient education content to ensure it is scientifically accurate, balanced, and free of inappropriate promotion. Coupon amounts, logistics vendors, and television taglines are commercial or operational decisions.

Question 24Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry

Which of the following best characterizes the concept of scientific exchange as used in Medical Affairs?

  1. A one-way promotional presentation delivered by sales representatives
  2. A two-way, non-promotional dialogue about scientific data between medical professionals and external experts Correct answer.
  3. A regulatory submission format for new drug applications
  4. A contractual agreement to purchase products at a discount

Explanation

Scientific exchange is a two-way, non-promotional dialogue in which medical professionals discuss data, respond to unsolicited questions, and gather expert insight. It is not a sales presentation, a purchasing contract, or a regulatory filing format.

Question 25Drug Development Process and Clinical Research

A sponsor is designing a first-in-human study and wants to characterize the pharmacokinetic profile of a new chemical entity. Which study design element is most appropriate for this objective?

  1. A crossover design comparing three marketed drugs
  2. An open-label registry with no pharmacokinetic sampling
  3. A fixed-dose parallel group with no placebo
  4. Single ascending dose cohorts with serial blood sampling Correct answer.

Explanation

First-in-human studies typically begin with single ascending dose cohorts that include intensive serial blood sampling to determine Cmax, Tmax, AUC, and half-life. Dose escalation is gradual to protect participants while characterizing exposure.

Question 26Drug Development Process and Clinical Research

In the standard drug development sequence, which phase primarily evaluates efficacy and safety in a larger patient population to support marketing approval?

  1. Phase I
  2. Phase II
  3. Phase IV
  4. Phase III Correct answer.

Explanation

Phase III trials enroll larger patient populations to confirm efficacy and establish a safety profile adequate to support regulatory submission. Phase II is exploratory and provides preliminary efficacy signals, while Phase IV occurs after approval.

Question 27Drug Development Process and Clinical Research

A randomized controlled trial uses a double-blind design. Which statement best describes what this design accomplishes?

  1. It eliminates the need for a control group in the study
  2. It prevents both participants and investigators from knowing treatment assignment Correct answer.
  3. It ensures every participant receives an active treatment at some point
  4. It guarantees that baseline characteristics are identical between arms

Explanation

Double blinding means neither the participants nor the investigator-assessors know the treatment assignment, which reduces performance and detection bias. Randomization and a control group remain necessary components of the design.

Question 28Drug Development Process and Clinical Research

Which document provides the ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve human participants?

  1. The Declaration of Helsinki only
  2. The Common Technical Document Module 3
  3. The Uniform Requirements for Manuscripts
  4. The ICH E6 Good Clinical Practice guideline Correct answer.

Explanation

ICH E6 Good Clinical Practice establishes the international ethical and scientific quality standard for trials involving human participants. It covers design, conduct, recording, and reporting of studies and is the basis for regulatory acceptance of trial data.

Question 29Drug Development Process and Clinical Research

A trial protocol specifies a primary endpoint, secondary endpoints, and a statistical analysis plan. Which of the following best describes the purpose of the primary endpoint?

  1. To answer the main research question and support the efficacy conclusion Correct answer.
  2. To describe the pharmacokinetic variability among subjects
  3. To provide exploratory data for future hypothesis generation
  4. To monitor laboratory abnormalities during treatment

Explanation

The primary endpoint is the variable that answers the main study question and is used to determine whether the trial met its objective. It must be pre-specified and linked to the sample size and analysis plan.

Question 30Drug Development Process and Clinical Research

During a clinical trial, a serious adverse event occurs. Within what general framework must the investigator report it to the sponsor?

  1. Only after the data safety monitoring board meets
  2. Immediately, according to the protocol and applicable regulatory timelines Correct answer.
  3. Only if the event is considered unrelated to the investigational product
  4. Only at the final study report

Explanation

Serious adverse events must be reported promptly to the sponsor according to the timelines defined in the protocol and applicable regulations, typically within 24 hours for immediate reporting. Delaying until study close or DSB review would compromise participant safety oversight.

Question 31Drug Development Process and Clinical Research

What is the primary purpose of a data safety monitoring board (DSMB) in a clinical trial?

  1. To audit the investigator site's financial records
  2. To recruit participants for the trial
  3. To prepare the marketing application for the sponsor
  4. To independently review accumulating safety and efficacy data and recommend continuation or modification Correct answer.

Explanation

A DSMB is an independent committee that periodically reviews unblinded accumulating data to protect participant safety and trial integrity. It can recommend continuing, modifying, or stopping the trial.

Question 32Drug Development Process and Clinical Research

A sponsor wants to reduce the risk of bias arising from differences in how participants are assigned to treatment groups. Which method best addresses this concern?

  1. Open-label treatment assignment
  2. Convenience sampling of available patients
  3. Central randomization with allocation concealment Correct answer.
  4. Historical control comparison

Explanation

Central randomization with allocation concealment prevents investigators from predicting or influencing treatment assignment, reducing selection bias. This is a core methodological safeguard in controlled trials.

Question 33Drug Development Process and Clinical Research

Which of the following best describes the role of a placebo control in a randomized trial?

  1. It eliminates the need for statistical analysis
  2. It provides a baseline against which the effect of the investigational product can be measured Correct answer.
  3. It replaces the need for informed consent
  4. It guarantees that all participants receive active drug

Explanation

A placebo control allows the effect of the investigational product to be distinguished from nonspecific effects such as natural fluctuation and placebo response. The comparison supports causal inference about treatment effect.

Question 34Drug Development Process and Clinical Research

A Phase II study is described as an exploratory dose-ranging trial. What is its main objective?

  1. To fulfill post-marketing safety commitments
  2. To establish the maximum tolerated dose in healthy volunteers
  3. To confirm long-term survival benefit in a large population
  4. To identify a dose and regimen for further evaluation and provide preliminary efficacy evidence Correct answer.

Explanation

Phase II trials explore dose-response and provide preliminary evidence of efficacy in patients, informing the design of confirmatory Phase III studies. They help select the dose and regimen to carry forward.

Question 35Drug Development Process and Clinical Research

A protocol includes a per-protocol analysis alongside an intention-to-treat analysis. Which statement best explains the difference?

  1. Both analyses include identical participant sets by definition
  2. Intention-to-treat excludes dropouts; per-protocol includes all randomized participants
  3. Intention-to-treat includes all randomized participants; per-protocol includes only those who adhered to the protocol Correct answer.
  4. Per-protocol analysis is used only for safety endpoints

Explanation

Intention-to-treat analyzes participants according to their randomized assignment and preserves randomization benefits, while per-protocol restricts analysis to those who completed treatment as specified. The two analyses answer different questions about effectiveness and biological effect.

Question 36Drug Development Process and Clinical Research

Which element is essential in an informed consent document for a clinical trial?

  1. A waiver of the participant's right to compensation for injury
  2. A statement that participation is voluntary and can be withdrawn at any time Correct answer.
  3. A requirement that the participant cannot ask questions after signing
  4. A guarantee that the investigational product will be effective

Explanation

Informed consent must state that participation is voluntary and that the participant may withdraw at any time without penalty. It must also describe risks, benefits, alternatives, and contact information.

Question 37Drug Development Process and Clinical Research

A trial's sample size calculation is based on detecting a specified difference with 80% power at a two-sided alpha of 0.05. If the expected effect size is smaller than assumed, what is the most likely consequence?

  1. The study will have lower power to detect the true effect Correct answer.
  2. The randomization will become invalid
  3. The type I error rate will increase to 0.10
  4. The primary endpoint will no longer be pre-specified

Explanation

Power depends on effect size, variability, sample size, and alpha; a smaller true effect than assumed reduces the probability of detecting a statistically significant difference. The study may therefore be underpowered.

Question 38Drug Development Process and Clinical Research

Which of the following describes the purpose of a Phase I study in healthy volunteers?

  1. To assess safety, tolerability, and pharmacokinetics of the investigational product Correct answer.
  2. To establish the manufacturing process validation
  3. To demonstrate superiority over the standard of care
  4. To evaluate quality of life in a large patient cohort

Explanation

Phase I studies typically evaluate safety, tolerability, and pharmacokinetics, often in small groups of healthy volunteers. They establish the dose range and exposure profile before patient studies.

Question 39Drug Development Process and Clinical Research

A sponsor plans to use an adaptive design in which pre-specified interim analyses allow sample size re-estimation. What is a key requirement for this design to be acceptable?

  1. The interim analyses must remain confidential to the sponsor only
  2. The adaptation rules must be pre-specified and control the type I error rate Correct answer.
  3. The design must avoid any statistical analysis plan
  4. The adaptation must occur after database lock

Explanation

Adaptive designs require pre-specified adaptation rules and statistical methods that preserve the overall type I error rate. Transparency and independent oversight of interim data are also important to maintain trial integrity.

Question 40Drug Development Process and Clinical Research

Which of the following best describes the role of a contract research organization (CRO) in drug development?

  1. It acts as the independent ethics committee for the trial
  2. It grants marketing authorization for the investigational product
  3. It performs delegated trial activities on behalf of the sponsor under a written agreement Correct answer.
  4. It owns the investigational product's patent

Explanation

A CRO provides outsourced services such as monitoring, data management, and statistical analysis under a written contract with the sponsor. The sponsor remains responsible for oversight of delegated activities.

Question 41Drug Development Process and Clinical Research

A trial uses a surrogate endpoint rather than a clinical outcome. What is the main limitation of relying on a surrogate endpoint for approval?

  1. It is only applicable to device studies
  2. It may not reliably predict the clinical benefit of interest Correct answer.
  3. It is always less precise than a clinical outcome
  4. It cannot be measured in a randomized trial

Explanation

Surrogate endpoints are biomarkers or intermediate measures that are expected to predict clinical benefit but are not themselves the outcome of interest. Their main limitation is that the relationship to clinical benefit may be uncertain or unvalidated.

Question 42Drug Development Process and Clinical Research

Which of the following is a key element of the ICH E6 Good Clinical Practice guideline regarding investigator responsibilities?

  1. The investigator may modify the protocol without notifying the sponsor
  2. The investigator must enroll a minimum of 500 participants
  3. The investigator must obtain approval from an independent ethics committee before initiating the trial Correct answer.
  4. The investigator may delegate all trial responsibilities without documentation

Explanation

Under GCP, the investigator must obtain ethics committee approval before initiating the trial and must conduct the study according to the approved protocol. Delegation must be documented, and protocol changes require appropriate approval.

Question 43Drug Development Process and Clinical Research

A sponsor is preparing a marketing application and must submit nonclinical and clinical summaries. Which Common Technical Document module contains the clinical study reports?

  1. Module 5 Correct answer.
  2. Module 1
  3. Module 2
  4. Module 3

Explanation

CTD Module 5 contains the clinical study reports and related clinical information. Module 2 provides summaries, Module 3 covers quality, and Module 1 contains regional administrative information.

Question 44Drug Development Process and Clinical Research

A trial protocol includes a plan for handling missing data. Why is this important for the validity of trial results?

  1. Missing data eliminate the need for randomization
  2. Missing data guarantee that the trial is unblinded
  3. Missing data can bias estimates and reduce power if not addressed appropriately Correct answer.
  4. Missing data always increase the treatment effect

Explanation

Missing outcome data can bias treatment comparisons and reduce statistical power, especially if missingness differs between arms. Pre-specified methods such as multiple imputation or sensitivity analyses help assess robustness of results.

Question 45Drug Development Process and Clinical Research

A sponsor is evaluating whether to use a non-inferiority design for a new antibiotic compared with an established therapy. Which consideration is most critical for this design?

  1. Ensuring the new drug is statistically superior to placebo
  2. Using a single-arm design without a comparator
  3. Requiring that the new drug have a faster onset of action
  4. Defining a non-inferiority margin justified by the historical effect of the active control Correct answer.

Explanation

Non-inferiority trials require a pre-specified margin that reflects the historical benefit of the active control over placebo, so that retaining a meaningful fraction of that effect can be inferred. Without a justified margin, the conclusion of non-inferiority is not interpretable.

Question 46Drug Development Process and Clinical Research

An investigator proposes to enroll a participant who does not meet an inclusion criterion but who might benefit from the investigational product. Under GCP, what is the appropriate action?

  1. Enroll the participant and document the deviation afterward
  2. Enroll the participant because clinical benefit overrides eligibility criteria
  3. Obtain a protocol amendment and ethics approval before enrollment, unless an emergency exception applies Correct answer.
  4. Ask the sponsor's medical monitor to waive the criterion informally

Explanation

Protocol eligibility criteria must be followed; deviations require a formal amendment and ethics approval unless an emergency situation justifies an exception to protect the participant. Informal waivers are not acceptable.

Question 47Drug Development Process and Clinical Research

A trial uses an enrichment design that enrolls only participants with a biomarker-defined subgroup. What is a principal trade-off of this strategy?

  1. Increased likelihood of detecting benefit in the targeted subgroup but reduced generalizability to the broader population Correct answer.
  2. Guaranteed elimination of all adverse events
  3. Automatic reduction in sample size without any statistical consequence
  4. Elimination of the need for a control group

Explanation

Enrichment designs increase the probability of showing benefit by focusing on a responsive subgroup, but the results may not generalize to biomarker-negative patients. Labeling and clinical use may therefore be restricted to the studied population.

Question 48Drug Development Process and Clinical Research

A trial's protocol specifies that the primary analysis will be conducted at a two-sided alpha of 0.05, and the sponsor adds a second primary endpoint after enrollment begins. What is the main statistical concern?

  1. Increased risk of unblinding
  2. Inflated type I error due to multiple comparisons without adjustment Correct answer.
  3. Loss of randomization
  4. Reduced need for informed consent

Explanation

Adding a co-primary endpoint changes the multiplicity structure and, without adjustment, increases the family-wise type I error rate. Pre-specification and appropriate multiplicity control are required to preserve valid inference.

Question 49Regulatory Affairs and Compliance

Under the MAB registration framework, which document is the primary instrument that establishes a manufacturer's legal authority to distribute a medical device in the jurisdiction?

  1. The device registration certificate issued by the regulatory authority Correct answer.
  2. The ISO 13485 quality management system certificate
  3. The distributor's commercial import license
  4. The clinical evaluation report prepared by the manufacturer

Explanation

The device registration certificate is the regulatory instrument that grants legal authority to place the device on the market after the authority has reviewed the technical file. ISO 13485 certification demonstrates quality system conformity but does not itself confer marketing authorization.

Question 50Regulatory Affairs and Compliance

A manufacturer makes a change to the sterilization method of an already registered device. What is the most appropriate regulatory action before the modified product is placed on the market?

  1. No action is needed because the device's intended purpose is unchanged
  2. Submit a variation or notification to the registration authority as required by the change classification Correct answer.
  3. Only update the internal quality manual and notify the distributor
  4. Wait until the next scheduled renewal of the registration

Explanation

Changes that could affect safety or performance, such as a change of sterilization method, generally require a variation or notification under the change-management provisions of the registration framework. The classification of the change determines whether prior approval or a simple notification applies.